Purpose: Androgen deprivation therapy is often used as salvage treatment in men with rising prostate specific antigen after initial radical prostatectomy or radiotherapy for clinically localized prostate cancer. Given the lack of evidence from general practice, we examined the association of salvage androgen deprivation therapy with mortality in an observational cohort study. Materials and Methods: From 3 managed care organizations we assembled a retrospective cohort of all 5,804 men with newly diagnosed localized prostate cancer from 1995 to 2009 who had a prostate specific antigen increase (biochemical recurrence) after primary radical prostatectomy or radiotherapy. The main outcomes were all-cause and prostate cancer specific mortality. We used Cox proportional hazards models to estimate mortality with salvage androgen deprivation therapy as a time dependent predictor. Results: Overall salvage androgen deprivation therapy was not associated with all-cause or prostate cancer specific mortality in the prostatectomy cohort (HR 0.97, 95% CI 0.70e1.35 or HR 1.18, 95% CI 0.68e2.07) or in the radiotherapy cohort (HR 0.84, 95% CI 0.70e1.01 or HR 1.06, 95% CI 0.80e1.40, respectively). Among men with prostate specific antigen doubling time less than 9 months after the prostate specific antigen rise, salvage androgen deprivation therapy was statistically significantly associated with a decreased risk of all-cause and prostate cancer specific mortality in the prostatectomy cohort (HR 0.35, 95% CI 0.20e0.63 and HR 0.43, 95% CI 0.21e0.91) and in the radiotherapy cohort (HR 0.62, 95% CI 0.48e0.80 and HR 0.65, 95% CI 0.47e0.90, respectively). Conclusions: We found no association of salvage androgen deprivation therapy with all-cause or cause specific mortality in most men with biochemical recurrence after primary radical prostatectomy or radiotherapy for clinically localized prostate cancer. Men with quickly progressed disease may derive a clinical benefit from salvage androgen deprivation therapy. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
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Supported by NCI (National Cancer Institute) of NIH (National Institutes of Health) Grants R01CA142934, RC1CA146238 and P30CA051008. In such men ADT is frequently prescribed as salvage therapy. 5e7 Some evidence suggests that SADT with radiotherapy may improve progression-free survival compared with radiation alone in men who undergo post-prostatectomy radiotherapy for increasing PSA, especially patients at high risk. 8 There are also conflicting data in the literature on the clinical benefits of early SADT in men with biochemical recurrence after radical prostatectomy. 9, 10 Importantly, the recently published, randomized clinical TOAD trial from multiple centers in Australia, New Zealand and Canada showed that immediate SADT improved overall survival compared with delayed SADT in men with biochemical recurrence after primary treatment with surgery with or without radiotherapy, or curative radiotherapy alone. 11 Nonetheless, this trial excluded patients with substantial medical comorbidities so that the results may not be generalizable to those typically seen in general practice.
The prolonged natural history of localized disease and the potential risks of adverse events associated with ADT use 12e14 add to the uncertainty of the effectiveness of SADT in men experiencing biochemical recurrence. Therefore, we assessed the association of SADT with all-cause and prostate cancer specific mortality in a population based cohort of men who experienced biochemical recurrence after undergoing initial curative localized therapies in general practice in the United States.
MATERIAL AND METHODS

Data Sources
All study data were obtained on men with newly diagnosed, clinically localized prostate cancer at 3 integrated health systems that participate in HCSRN (Health Care System Research Network), including Kaiser Permanente Northern California, Kaiser Permanente Southern California and the Henry Ford Health System, Detroit, Michigan. 15 These 3 health care systems have electronic health records that incorporate comprehensive information from all inpatient and outpatient clinical encounters, laboratory test values, and pharmacy and cancer registry data.
Cohort Selection
We identified all 51,511 men 35 years old or older who were diagnosed with clinically localized prostate cancer (T1-T2, N0, M0) from January 1, 1995 through January 1, 2009 (see figure) . We included men with node negative disease who received primary therapy with radical prostatectomy or radiotherapy within 12 months after the initial prostate cancer diagnosis. We excluded men who received primary ADT, orchiectomy or chemotherapy as part of initial therapy due to an indication of metastatic disease and those with less than 2 years of followup to ensure sufficient time to identify SADT exposure (see figure) .
In this group we identified 5,804 men with evidence of a post-primary therapy PSA increase (biochemical recurrence). In the 2,676 men who underwent prostatectomy we defined the PSA rise as PSA 0.2 ng/ml or greater. 8, 11, 16, 17 In the 3,128 men treated with primary radiotherapy (external beam or brachytherapy) we defined the PSA rise as 2.0 ng/ml or greater above the PSA nadir (the lowest PSA observed), or 10.0 ng/ml or greater. 11, 18 We used the date of the PSA increase as time zero for survival analysis.
Salvage Androgen Deprivation Therapy
We captured ADT use (gonadotropin releasing hormone analogues or antagonists) from pharmacy records. SADT was defined as the ADT that commenced on the date after the first post-primary therapy PSA rise. We considered ADT as adjuvant rather than salvage therapy if it was given before any observed PSA increase after primary therapy.
Mortality Outcomes
We captured all-cause and prostate cancer specific mortality (C619, C61 and 185) based on ICD-10 codes. Date and cause of death information was derived from a combination of clinical data sets, probabilistic linkage with death certificate records from California or Michigan and linkage with SSA (Social Security Administration) data to ascertain deaths that occurred outside California or Michigan. Each man was followed through the date of death or the end of study period on December 31, 2010, whichever occurred first. Median followup was 8 years (range 2 to 15).
Baseline and Post-Primary Therapy Characteristics
We obtained certain variables from the cancer registries and electronic health records of each health plan, including age at the PSA rise, racial/ethnic group, year of diagnosis and diagnosis of prior or subsequent primary cancers other than prostate cancer (tumor sequence). The AUA risk group at baseline was assessed based on PSA, Gleason score and clinical T stage. 17, 19 Low risk was defined as PSA 10 ng/ml or less, Gleason score 6 or less and stages T1c-T2a. Intermediate risk was defined as PSA 11 to 20 ng/ml, Gleason score 7 or stage T2b. High risk was defined as PSA greater than 20 ng/ml, Gleason score 8 or greater, or stages T2c-3a. We calculated the Elixhauser comorbidity index by assessing the presence of 30 individual health conditions diagnosed between 2 years before the prostate cancer diagnosis date up to 3 months after the diagnosis. 20 We included time from primary therapy to the PSA increase as a covariate on multivariate analysis. We calculated PSA doubling time based on PSA values after primary therapy until the receipt of SADT or to the end of followup in men without SADT (supplementary Appendix, http://jurology.com/). 21, 22 If men underwent primary prostatectomy, we adjusted for the receipt of radiotherapy for recurrence or progression.
Statistical Analysis
We analyzed mortality outcomes separately in men initially treated with primary radical prostatectomy or radiotherapy because we used different definitions of PSA increase and some baseline characteristics varied by primary treatment group. 18 We calculated person-year mortality rates according to SADT use for descriptive purpose only.
Due to the varying timing of SADT initiation we treated SADT as a time dependent variable in the Cox proportional hazards model to estimate the HR of each mortality outcome. In each model followup started with the date of the PSA rise and ended with death as the outcome event or the end of followup. We adjusted for multiple patient clinical and sociodemographic characteristics. The supplementary Appendix (http://jurology. com/) describes the methods of assessing proportional hazards assumption and handling missing data.
To assess for effect modification by the timing of SADT initiation we performed sensitivity analyses categorizing SADT into 3 levels, including 1) SADT initiated within 12 months, 2) SADT initiated beyond 12 months and 3) no SADT after the PSA increase. We also performed subgroup analyses according to age at PSA rise, race/ethnicity, comorbidity, baseline AUA risk group and PSA doubling time. 
RESULTS
Patient Characteristics
We observed 2,676 men (16.3%) with rising PSA after primary prostatectomy. Mean AE SD age at the PSA increase was 66 AE 7.8 years. Overall patients had a PSA rise a median 2.3 years after prostatectomy. There were 844 men who received SADT with 7,070 person-years of followup and 1,832 without SADT had 14,582 person-years of followup.
A total of 3,128 men (16.0%) had increasing PSA after primary radiotherapy. Mean age at the time of the PSA rise was 72 AE 7.8 years. Overall patients had a PSA increase a median 3.9 years after primary radiotherapy. Patient baseline demographic and clinical characteristics, as well as post-primary therapy characteristics are shown by their primary therapies (supplementary 
Mortality Outcomes
In unadjusted comparisons SADT vs no SADT was associated with higher all-cause mortality (14.4 vs 9.8 deaths per 1,000 person-years) and higher prostate cancer specific mortality (6.8 vs 2.4 deaths per 1,000 person-years) in patients treated with prostatectomy. However, after adjusting for all covariates we found no association of SADT use with all-cause mortality (HR 0.97, 95% CI 0.70e1.35) or prostate cancer specific mortality (HR 1.18, 95% CI 0.68e2.07, table 1). Similarly, there was no statistically significant association of SADT with the risk of all-cause mortality (HR 0.84, 95% CI 0.70e1.01) or prostate cancer specific mortality (HR 1.06, 95% CI 0.80e1.40) after adjustment in patients who received radiotherapy (table 1) .
Sensitivity Analysis of Salvage Androgen Deprivation Therapy Timing
We next performed sensitivity analyses assessing the timing of SADT initiation in our cohort (table 2) . After adjustment we observed larger HRs for allcause mortality (2.27, 95% CI 1.51e3.41) and prostate cancer specific mortality (2.43, 95% CI 1.21e4.86) in patients treated with prostatectomy without SADT compared with those who received SADT within 12 months after the PSA rise. Similarly, in patients who received primary radiotherapy no SADT was associated with a higher risk of all-cause mortality (2.41, 95% CI 1.96e2.96) and prostate cancer specific mortality (2.25, 95% CI 1.67e3.05) compared with patients who received SADT within 12 months after the PSA increase.
Subgroup Analyses
Among men with PSA doubling time less than 9.0 months we observed that SADT was associated with a decreased risk of all-cause mortality (HR 0.35, 95% CI 0.20e0.63) and prostate cancer specific mortality (HR 0.43, 95% CI 0.21e0.91) in those initially treated with prostatectomy (table 3) . Similar findings were identified in men initially treated with radiotherapy who had PSA doubling time less than 9.0 months with a significant association between SADT and a decreased risk of all-cause mortality (HR 0.62, 95% CI 0.48e0.80) and prostate cancer specific mortality (HR 0.65, 95% CI 0.47e0.90). No significant associations were observed in men with slower PSA doubling time except for all-cause mortality in those initially treated with prostatectomy and with PSA doubling time 9.0 to less than 15.0 months (HR 0.32, 95% CI 0.11e0.92).
In the radiotherapy group we observed that SADT was associated with a decreased risk of allcause mortality in men 75 years old or older (HR 0.71, 95% CI 0.55e0.93) and in white men (HR 0.75, 95% CI 0.61e0.92) but there was no association with prostate cancer specific mortality.
DISCUSSION
ADT has been increasingly used as salvage therapy in men experiencing biochemical recurrence following primary therapy with prostatectomy or radiotherapy 2,4e6 despite limited evidence for a survival benefit in general practice. 11 Overall our finding of no association of SADT with mortality does not support SADT as an effective treatment in most men who had clinically localized prostate cancer and experienced biochemical recurrence. However, we identified significant benefits on allcause and prostate cancer specific mortality associated with SADT use in the subgroup of men with PSA doubling time less than 9 months after primary therapy. Such findings help inform and guide current practice in the general population.
Additionally, any survival benefits of SADT must be carefully weighed against quality of life and the potentially serious adverse effects of ADT, including We observed a lower 16% rate of PSA increase than in the literature 2e4 due to a younger study population, a more restrictive definition of PSA rise using electronic health records and a lack of mandated PSA testing. Our sensitivity analysis on the timing of SADT after rising PSA implied a decreased risk of all-cause and prostate cancer specific mortality among men who received SADT within 12 months after the PSA increase. This is consistent with the TOAD trial, which supports immediate rather than delayed receipt of ADT in men with biochemical recurrence after primary therapies. 11 However, we identified significant differences only between men who received SADT within 12 months and men in whom no SADT was observed after the PSA rise. The latter group could be mixed with varying followup times, possibly also less than 12 months due to censoring. Additionally, we detected no mortality differences between SADT initiation within 12 months and beyond 12 months after the PSA increase. Therefore, the timing effect of SADT use cannot be fully confirmed based on our results. Notably our subgroup analysis revealed associations of SADT with both all-cause mortality and prostate cancer specific mortality in men with PSA doubling time less than 9 months. Such results suggest a clinical benefit from SADT in men in whom disease quickly progresses with a rapid PSA doubling time. This confirms a recently published systematic review. 27 Similarly, the TOAD trial was stratified by PSA doubling time, 11 suggesting that it is a predictive factor for implementing earlier ADT.
Additionally, our results suggest a decreased risk of all-cause mortality in men who underwent primary prostatectomy and who had PSA doubling time between 9.0 and 15.0 months. However, since we did not detect an association of SADT with cause specific mortality, it is possible that this finding for all-cause mortality may be partly due to selection bias, ie healthier men at the time of increasing PSA were more likely to receive SADT than those with lower life expectancy. Our statistical adjustments of observed differences in age and comorbidity are not likely to fully account for differences in baseline health status among patients.
Further, our subgroup analysis detected associations between SADT and all-cause mortality in nonHispanic white men and in men 75 to 90 years old receiving primary radiotherapy. This finding may also be due partly to selection bias and the observed benefits were small. Thus, the use of SADT in older men after primary radiotherapy should be carefully weighed against its possible risks in terms of side effects.
The current analysis has several strengths. We studied a large, heterogeneous, population based sample of 36,000 men with localized prostate cancer treated with primary prostatectomy or radiotherapy, including approximately 6,000 with evidence of a PSA rise and 926 who died. We accounted for baseline prognostic factors and considered longitudinal PSA values, which are critical to determine biochemical recurrence. Also, our results are more applicable to patients in the general practice compared to findings in the TOAD trial. 11 With a median followup of 5 years in that trial only 40% of men in the delayed arm avoided SADT compared to 60% in our study with a median followup of 8 years, suggesting a lower risk group. Thus, advising patients on the risks and benefits of starting SADT must be based on their risk factors for progression.
Our findings are subject to limitations. 1) Because we lacked information on bone metastasis and imaging results, we cannot be certain that the increase in PSA was truly only a biochemical recurrence. However, since rising PSA often occurs many years before metastases develop, 7 the majority of the men in our sample with rising PSA are unlikely to have had bone metastasis.
2) We could not address unobserved confounders from the electronic health records, such as the reasons for SADT initiation, physician or patient preferences, health status or behaviors.
3) It is possible that certain patients may have been treated with SADT after the end of followup but they were classified as not having received SADT based on our definition. 4) Effects based on the duration of ADT exposure or the differentiation of intermittent vs continuous ADT were not addressed in this study. However, in light of findings of equivocal mortality when comparing intermittent vs continuous ADT for rising PSA, 28 the specific type of ADT administration is not likely to influence the outcomes that we observed for SADT. 5) Our cutoff points for PSA doubling time were based on our data distribution and previous studies 17, 29 but they were still arbitrary. 6) Our cohort consisted of members of integrated managed care plans. This may potentially limit the generalizability of our findings to men treated in fee-for-service settings, for example. However, the populations covered by the 3 health plans are sociodemographically diverse and the plans include Medicare and Medicaid patients.
CONCLUSIONS
We found that treating rising PSA with SADT after primary prostatectomy or radiotherapy for clinically localized prostate cancer was not associated with all-cause or prostate cancer specific mortality in most men. Nonetheless, on subgroup analysis we identified that statistically significant benefits on mortality were associated with SADT. Given the study limitations, any true benefit of SADT should be carefully weighed against the known side effects of ADT.
